#ASH22 roundup: CSL shows two years of data in $3.5M hemophilia gene therapy; Syndax shows 30% CR rate from March data cut

NEW ORLEANS — CSL Behring made headlines last month after the FDA gave approval to the biotech for its hemophilia B gene therapy with a …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#ASH22 roundup: CSL shows two years of da­ta in $3.5M he­mo­phil­ia gene ther­a­py; Syn­dax shows 30% CR rate from March da­ta cut